QUADRAMET Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Quadramet, and what generic alternatives are available?
Quadramet is a drug marketed by Lantheus Medical and is included in one NDA.
The generic ingredient in QUADRAMET is samarium sm-153 lexidronam pentasodium. Additional details are available on the samarium sm-153 lexidronam pentasodium profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for QUADRAMET?
- What are the global sales for QUADRAMET?
- What is Average Wholesale Price for QUADRAMET?
Summary for QUADRAMET
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 8 |
Clinical Trials: | 3 |
Drug Prices: | Drug price information for QUADRAMET |
What excipients (inactive ingredients) are in QUADRAMET? | QUADRAMET excipients list |
DailyMed Link: | QUADRAMET at DailyMed |
Recent Clinical Trials for QUADRAMET
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
National Cancer Institute (NCI) | Phase 1/Phase 2 |
Mayo Clinic | Phase 1/Phase 2 |
Sidney Kimmel Cancer Center at Thomas Jefferson University | Phase 1 |
US Patents and Regulatory Information for QUADRAMET
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lantheus Medical | QUADRAMET | samarium sm-153 lexidronam pentasodium | INJECTABLE;INJECTION | 020570-001 | Mar 28, 1997 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for QUADRAMET
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Lantheus Medical | QUADRAMET | samarium sm-153 lexidronam pentasodium | INJECTABLE;INJECTION | 020570-001 | Mar 28, 1997 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for QUADRAMET
See the table below for patents covering QUADRAMET around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Japan | 2922263 | ⤷ Sign Up | |
Ireland | 902812 | ⤷ Sign Up | |
Norway | 178196 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for QUADRAMET
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0164843 | C980021 | Netherlands | ⤷ Sign Up | PRODUCT NAME: SAMARIUM[153 SM] LEXIDRONAM, DESGEWENST IN DE VORM VAN EEN FYSI OLOGISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET PENTANATRIUMZO UT; NAT.REGISTRATION NO/DATE: C(1998)253 DEF 19980205; FIRST REGISRATION: EU/1/97/057/001 19980205 |
0164843 | SPC/GB98/028 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: 153 SAMARIUM ETHYLENEDIAMINETETRAMETHYLENEPHOSPHONIC ACID (QUADRAMET); REGISTERED: CH CH 54265 19971006; UK EU/1/97/057/001 19980205 |
0164843 | 98C0023 | Belgium | ⤷ Sign Up | PRODUCT NAME: SAMARIUM (153 SM) LEXIDRONAM PENTASODIQUE; NAT. REGISTRATION NO/DATE: EU/1/97/057/001 19980205; FIRST REGISTRATION: CH 54265 19971006 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |